ProCE Banner Activity

Phase II Trial of Vemircopan (ALXN2050) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria

Slideset Download
Conference Coverage

Vemircopan monotherapy demonstrated control of intravascular hemolysis, prevention of clinically significant extravascular hemolysis, and improvement in fatigue in treatment-naive patients with PNH.

Released: December 16, 2022

Expiration: December 15, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen